Idarubicin is a type of medicine used to treat certain types of cancer. It's a strong chemotherapy drug that works by killing cancer cells. It's given to patients, often through an IV line, to help fight the cancer.
Every report comes from a Lived member, sent anonymously.
Have you tried Idarubicin for AML (Acute Myeloid Leukemia)?
Idarubicin is an intravenous chemotherapy medicine used mainly to treat acute myeloid leukemia (AML), a fast-growing cancer of the blood-forming cells in the bone marrow. In the US it is sold as Idamycin PFS and as generic idarubicin hydrochloride injection, and it is approved for adults with AML as part of a combination regimen. It is most often paired with another chemotherapy drug, cytarabine, during induction: the first intensive phase of treatment, which aims to clear leukemia cells from the blood and bone marrow and bring the disease into remission. Daunorubicin, a closely related drug, is the usual alternative in the same role, and current evidence does not clearly favor one over the other. Specialists also use idarubicin in some regimens beyond its label. In acute promyelocytic leukemia (APL), a distinct subtype of AML, people with higher-risk disease (a white blood cell count above 10,000 per microliter at diagnosis) are often treated with all-trans retinoic acid (ATRA, a vitamin A-related medicine taken by mouth) combined with an anthracycline, and idarubicin is the one used in well-known regimens of this kind. It also appears in some treatments for AML that has come back or has not responded, such as the combination called FLAG-Ida. Its safety and effectiveness in children have not been established by the FDA label, so pediatric use is a specialist decision.
Idarubicin belongs to the anthracyclines, a family of chemotherapy drugs that also includes daunorubicin and doxorubicin. Before a cell divides, it has to copy its DNA. Idarubicin binds to DNA and blocks topoisomerase II, an enzyme cells use to untangle and reseal DNA strands during copying. It also produces reactive molecules that damage DNA directly. Cells with this damage cannot divide properly, and many of them die. Leukemia cells divide rapidly, so they are especially exposed to this effect. The drug cannot tell them apart from healthy cells that also divide quickly, including the bone marrow cells that make normal blood cells, the lining of the mouth and gut, and hair follicles. That is why low blood counts, mouth sores and hair loss are expected parts of treatment rather than unusual reactions.
Idarubicin is given only into a vein, by trained staff in a hospital or cancer center. Each dose runs in over about 10 to 15 minutes. In standard AML induction it is given once a day for the first three days, while cytarabine runs as a continuous infusion for seven days (a pattern often called 7 + 3). If leukemia remains after the first round, a second induction round may be given. Other regimens, such as those for APL, use a different schedule. The dose is calculated from body surface area, which is based on height and weight. It may be lowered for kidney or liver problems, or after severe low blood counts or mouth sores in an earlier round. Because the heart risk depends on the total amount of anthracyclines a person receives over a lifetime, the team counts every dose of idarubicin and related drugs, including any given years earlier. If idarubicin leaks out of the vein into the surrounding tissue, it can cause blistering, open sores and tissue death that may need surgery and skin grafts. Tell the nurse at once about burning, stinging, pain or swelling at the IV site during the infusion, and contact the care team if pain at the site appears afterward.
Because induction is intensive, most people have several side effects. In clinical trials the most common were infections, nausea and vomiting, hair loss, abdominal pain or diarrhea, bleeding, and mucositis (painful sores and inflammation of the mouth and digestive tract). Rashes, fever, headache, confusion or other changes in thinking, and lung problems were also frequent. Hair loss affects most people and usually grows back. Urine can turn red for a short time after a dose; this is the drug's color and is not a sign of bleeding on its own. The most important effect is a deep drop in blood counts. Low white blood cells leave the body open to serious infection, low platelets make bleeding more likely, and low red blood cells cause tiredness and breathlessness; red cell and platelet transfusions are a routine part of care. With very low white counts, an infection can become life threatening quickly. Contact the care team right away, at any hour, for a fever, chills or other signs of infection, and for unusual bleeding or bruising, such as nosebleeds, bleeding gums or blood in the stool. When many leukemia cells die at once, they release their contents into the blood, which can upset blood chemistry and strain the kidneys. This is called tumor lysis syndrome. The team watches for it with frequent blood tests in the first days of treatment and prevents it with fluids and medicines such as allopurinol.
Idarubicin carries an FDA boxed warning, the strongest kind, for three risks. The first is damage to the heart muscle that can lead to heart failure, either during treatment or years later. The risk grows with the total lifetime dose of anthracyclines and is higher after previous anthracyclines, radiation to the chest, or other medicines that can harm the heart, and in people with existing heart disease and older adults. Heart pumping strength is measured before treatment, usually with an echocardiogram (an ultrasound of the heart) or a MUGA scan (a nuclear medicine scan of the heart's pumping), and checked again during and after treatment. Contact the care team immediately for new or worsening shortness of breath or cough, swelling of the legs, ankles or face, a fast or irregular heartbeat, weight gain of more than 5 pounds in 24 hours, dizziness or fainting, whether during treatment or after it ends. The second is a higher chance of developing a new blood cancer later, such as a second AML or myelodysplastic syndrome (MDS), a disorder in which the bone marrow makes faulty blood cells. The third is the tissue damage that can follow a leak from the vein, described under Dosage & Administration. Kidney or liver problems can make side effects stronger, so blood tests of both are done before and during treatment, and the drug is avoided when liver function is severely impaired. Allergic reactions such as rash or hives can occur. Idarubicin can harm a developing baby, so a pregnancy test is done beforehand in anyone who could become pregnant. Women who could become pregnant should use effective birth control during treatment and for 6.5 months after the last dose; men with partners who could become pregnant should do so for 3.5 months after the last dose. Breastfeeding should stop during treatment and for 14 days after. Idarubicin may also reduce fertility in both men and women, and it is not known whether this recovers.
Induction is demanding and closely supervised. Blood counts are checked often, transfusions are common while the bone marrow recovers, and fevers are treated promptly with antibiotics. Nausea medicines, mouth care and attention to hand hygiene and early signs of infection are part of daily routine during this period. The first goal is complete remission, meaning no detectable leukemia in standard tests. About 60% to 70% of adults with AML reach remission after induction, although results vary widely with age, overall health and the genetic features of the leukemia. Remission is a milestone rather than the end of treatment: further treatment after remission is aimed at keeping the leukemia from returning, and the plan depends on the leukemia's risk profile. The effects of idarubicin can outlast treatment. Heart checks may continue periodically for years, especially after higher total anthracycline doses, and doctors stay alert for the small chance of a second blood cancer during long-term follow-up.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Idarubicin, what you've noticed, or ask the community a question.